[go: up one dir, main page]

IN2014CN04590A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04590A
IN2014CN04590A IN4590CHN2014A IN2014CN04590A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A IN 4590CHN2014 A IN4590CHN2014 A IN 4590CHN2014A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A
Authority
IN
India
Prior art keywords
nucleic acid
acid strand
nucleotides
nucleotide analogs
transcription product
Prior art date
Application number
Other languages
English (en)
Inventor
Takanori Yokota
Kazutaka Nishina
Satoshi Obika
Hidehiro Mizusawa
Original Assignee
Nat Univ Corp Tokyo Med & Dent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Corp Tokyo Med & Dent filed Critical Nat Univ Corp Tokyo Med & Dent
Publication of IN2014CN04590A publication Critical patent/IN2014CN04590A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN4590CHN2014 2011-12-16 2012-12-17 IN2014CN04590A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011275488 2011-12-16
PCT/JP2012/083180 WO2013089283A1 (fr) 2011-12-16 2012-12-17 Acide nucléique double brin chimérique

Publications (1)

Publication Number Publication Date
IN2014CN04590A true IN2014CN04590A (fr) 2015-09-18

Family

ID=47559626

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4590CHN2014 IN2014CN04590A (fr) 2011-12-16 2012-12-17

Country Status (9)

Country Link
US (6) US9816089B2 (fr)
EP (1) EP2791335B1 (fr)
JP (7) JP6112569B2 (fr)
CN (2) CN104126010B (fr)
AU (1) AU2012353330B2 (fr)
CA (2) CA3106312C (fr)
ES (1) ES2707232T3 (fr)
IN (1) IN2014CN04590A (fr)
WO (1) WO2013089283A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN00720A (fr) 2009-07-06 2015-06-19 Ontorii Inc
WO2012039448A1 (fr) 2010-09-24 2012-03-29 株式会社キラルジェン Groupe auxiliaire asymétrique
MX347361B (es) 2011-07-19 2017-04-12 Wave Life Sciences Ltd Metodos para la sintesis de acidos nucleicos funcionalizados.
CA3106312C (fr) * 2011-12-16 2025-09-23 National University Corporation Tokyo Medical And Dental University Acide nucleique double brin chimerique
EP2872485B1 (fr) 2012-07-13 2020-12-16 Wave Life Sciences Ltd. Groupe auxiliaire asymétrique
AU2014222150A1 (en) * 2013-03-01 2015-09-10 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
WO2014148620A1 (fr) * 2013-03-21 2014-09-25 国立大学法人東京医科歯科大学 Liants d'acide nucléique double brin, complexe dudit liant-acide nucléique double brin, composition pharmaceutique contenant ledit complexe et procédé de production dudit complexe
CA2915443A1 (fr) * 2013-06-16 2014-12-24 National University Corporation Tokyo Medical And Dental University Acide nucleique antisens a double brin ayant un effet de saut d'exon
JP6482475B2 (ja) * 2014-01-07 2019-03-13 レナセラピューティクス株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
JP6892433B2 (ja) 2015-04-03 2021-06-23 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 十分に安定化された非対称ｓｉｒｎａ
US10633653B2 (en) 2015-08-14 2020-04-28 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
JP2018528783A (ja) 2015-09-25 2018-10-04 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． コンジュゲートアンチセンス化合物及びその使用
EP3366773A4 (fr) * 2015-10-23 2019-06-12 Rena Therapeutics Inc. Complexe d'acides nucléiques
JPWO2017068791A1 (ja) * 2015-10-23 2018-08-09 レナセラピューティクス株式会社 少なくとも１つのバルジ構造を有する核酸複合体
JP6950958B2 (ja) * 2015-12-01 2021-10-13 国立大学法人 東京医科歯科大学 核酸を含む経腸投与用組成物
MX2018009090A (es) * 2016-01-26 2019-03-28 Nissan Chemical Corp Oligonucleótido de cadena simple.
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
US11433089B2 (en) 2016-09-23 2022-09-06 National University Corporation Tokyo Medical And Dental University Blood-brain barrier permeable heteroduplex nucleic acid
US11260134B2 (en) 2016-09-29 2022-03-01 National University Corporation Tokyo Medical And Dental University Double-stranded nucleic acid complex having overhang
EP3584319A4 (fr) * 2017-02-06 2021-04-14 Nissan Chemical Corporation Oligonucléotide monobrin
EP3603648B1 (fr) 2017-03-29 2025-09-17 Shionogi & Co., Ltd Complexe de médicament d'acide nucléique et de lipide multiramifié
EP3604531A4 (fr) * 2017-03-31 2020-12-23 Aichi Medical University Acide nucléique antisens pour l'inhibition de la biosynthèse de sulfate de chondroïtine
US20200115710A1 (en) * 2017-06-30 2020-04-16 National University Corporation Tokyo Medical And Dental University HETERO DOUBLE-STRANDED antimiR
JP7384033B2 (ja) * 2017-07-26 2023-11-21 日産化学株式会社 一本鎖オリゴヌクレオチド
EP4257691A3 (fr) 2017-12-14 2024-01-10 Ionis Pharmaceuticals, Inc. Composés antisens conjugués et leur utilisation
WO2019167995A1 (fr) 2018-02-28 2019-09-06 国立大学法人東京医科歯科大学 Thérapie génique spécifique du siège d'une lésion ischémique
US11851654B2 (en) 2018-03-19 2023-12-26 National University Corporation Tokyo Medical And Dental University Nucleic acid with reduced toxicity
KR20190110043A (ko) * 2018-03-19 2019-09-27 주식회사 케이티 비디오 신호 처리 방법 및 장치
MX2020009765A (es) 2018-03-20 2021-01-08 Tokyo Inst Tech Oligonucleotido antisentido reducido en toxicidad.
JP7262816B2 (ja) * 2018-03-22 2023-04-24 国立大学法人 東京医科歯科大学 ヘテロ核酸のｂｂｂ通過脂質リガンド
WO2020150636A1 (fr) * 2019-01-18 2020-07-23 University Of Massachusetts Ancres de modification pharmacocinétique dynamique
JP7687682B2 (ja) * 2019-04-08 2025-06-03 国立大学法人東京科学大学 筋疾患治療用医薬組成物
JP7692829B2 (ja) 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
WO2021070959A1 (fr) 2019-10-11 2021-04-15 国立大学法人東京医科歯科大学 Acide heteronucléique modifié
EP4090744A4 (fr) * 2020-01-17 2024-04-10 Anastasia Khvorova Ancres de modification pharmacocinétique dynamique universelles
JP7753106B2 (ja) 2020-01-31 2025-10-14 株式会社三和化学研究所 Ａｔｎ１のアンチセンスオリゴヌクレオチド
JPWO2021177418A1 (fr) 2020-03-04 2021-09-10
JPWO2021187392A1 (fr) * 2020-03-16 2021-09-23
CN115968374A (zh) 2020-06-15 2023-04-14 Liid制药股份有限公司 交联型核苷及核苷酸
CA3202708A1 (fr) 2020-11-23 2022-05-27 Alpha Anomeric Sas Duplex d'acides nucleiques
EP4298251A4 (fr) * 2021-02-26 2025-03-19 Northwestern University Biocapteurs acellulaires avec circuits de deplacement de brins d'adn
US20240240183A1 (en) * 2021-05-25 2024-07-18 National University Corporation Tokyo Medical And Dental University Heteronucleic acid containing scpBNA or AmNA
CN117412773A (zh) 2021-05-31 2024-01-16 瑞纳治疗公司 配体结合核酸复合物
EP4389891A4 (fr) * 2021-08-19 2025-10-29 Univ Nat Corp Tokyo Medical & Dental Acide héteronucléique modifié contenant de l'acide nucléique morpholino
WO2023026994A1 (fr) 2021-08-21 2023-03-02 武田薬品工業株式会社 Conjugué peptide-médicament liant le récepteur de la transferrine humaine
WO2023042876A1 (fr) 2021-09-15 2023-03-23 国立大学法人東京医科歯科大学 Acide hétéronucléique comprenant un nucléoside 2'-modifié
EP4415827A4 (fr) * 2021-10-14 2025-12-03 Univ Arizona State Plates-formes de distribution programmables pour structures d'arn
WO2023080159A1 (fr) 2021-11-02 2023-05-11 レナセラピューティクス株式会社 Complexe d'acide nucléique lié à un ligand
US20250297249A1 (en) * 2021-12-07 2025-09-25 Liid Pharmaceuticals, Inc. Antisense oligonucleotide complex
EP4596694A1 (fr) 2022-09-29 2025-08-06 Institute Of Science Tokyo Molécule d'acide nucléique contenant une modification 5'-cyclopropylène
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024228398A1 (fr) * 2023-05-02 2024-11-07 国立大学法人東京医科歯科大学 Agent d'acide nucléique pour induire une structure g-quadruplex

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110894A (ja) * 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
WO1999014226A2 (fr) 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US20030104401A1 (en) 2001-11-12 2003-06-05 Epiclone, Inc. Gene silencing using sense DNA and antisense RNA hybrid constructs
AU2003247521A1 (en) * 2002-06-26 2004-01-19 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
DE10240417A1 (de) 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
US20040137471A1 (en) * 2002-09-18 2004-07-15 Timothy Vickers Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds
EP2336318B1 (fr) 2002-11-13 2013-04-24 Genzyme Corporation Modulation antisens de l'expression d'apolipoproteine b
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
BRPI0413930A (pt) * 2003-09-18 2006-10-24 Isis Pharmaceuticals Inc composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
AU2011204898A1 (en) * 2004-04-09 2011-08-11 Biodelivery Sciences International, Inc Nucleotide-cochleate compositions and methods of use
WO2005113571A2 (fr) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methodes de delivrance de composes d'oligomeres
BRPI0519690A2 (pt) 2004-12-30 2009-03-03 Todd M Hauser composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos
EP2505646A1 (fr) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Composés et procédés pour moduler lýexpression de CRP
EP2057187B1 (fr) 2006-08-10 2016-12-28 Oncotherapy Science, Inc. Gènes et polypeptides associés à des cancers du sein
WO2008029619A1 (fr) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
CA2666191C (fr) 2006-10-09 2017-07-11 Santaris Pharma A/S Composes antagonistes de l'arn pour la modulation de pcsk9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US7858592B2 (en) * 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
WO2008111908A1 (fr) * 2007-03-15 2008-09-18 Jyoti Chattopadhyaya Ribothymidines carbocycliques 2', 4' à conformation verrouillée à 5 et 6 éléments destinées à traiter des infections et le cancer
WO2009099326A1 (fr) * 2008-02-08 2009-08-13 Prosensa Holding Bv Méthodes et moyens pour traiter les affections génétiques associées à l’instabilité de répétition d’adn
EP2133425A1 (fr) 2008-06-13 2009-12-16 Karin Mölling Procédé et composé de thérapie antivirale (VIH)
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
DK3252068T3 (da) * 2009-10-12 2025-08-25 Larry J Smith Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
CA3106312C (fr) 2011-12-16 2025-09-23 National University Corporation Tokyo Medical And Dental University Acide nucleique double brin chimerique
CN105264073A (zh) * 2013-05-30 2016-01-20 国立大学法人东京医科齿科大学 用于递送治疗性寡核苷酸的双链剂

Also Published As

Publication number Publication date
JP2021011501A (ja) 2021-02-04
US20210340540A1 (en) 2021-11-04
CA2859581C (fr) 2022-03-22
JP6416301B2 (ja) 2018-10-31
JP2020039364A (ja) 2020-03-19
CN104126010A (zh) 2014-10-29
JP6638923B2 (ja) 2020-02-05
AU2012353330A1 (en) 2014-07-31
JP6112569B2 (ja) 2017-04-12
AU2012353330B2 (en) 2018-04-19
US20240158790A1 (en) 2024-05-16
JP2017140031A (ja) 2017-08-17
EP2791335A1 (fr) 2014-10-22
JP7174384B2 (ja) 2022-11-17
WO2013089283A1 (fr) 2013-06-20
US11034955B2 (en) 2021-06-15
CN104126010B (zh) 2021-04-06
US20140302603A1 (en) 2014-10-09
CN112386605A (zh) 2021-02-23
CA2859581A1 (fr) 2013-06-20
US10329567B2 (en) 2019-06-25
JP2015502134A (ja) 2015-01-22
US12344841B2 (en) 2025-07-01
JP7423015B2 (ja) 2024-01-29
US20190270996A1 (en) 2019-09-05
CA3106312C (fr) 2025-09-23
US20180320181A1 (en) 2018-11-08
US9816089B2 (en) 2017-11-14
EP2791335B1 (fr) 2018-11-14
JP2022000426A (ja) 2022-01-04
CA3106312A1 (fr) 2013-06-20
JP6960123B2 (ja) 2021-11-05
US10337006B2 (en) 2019-07-02
ES2707232T3 (es) 2019-04-03
JP2022171811A (ja) 2022-11-11
JP2018203779A (ja) 2018-12-27
US20180073024A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
IN2014CN04590A (fr)
HK1221978A1 (zh) Tmprss6 irna组合物及其使用方法
IN2013MN00522A (fr)
EP2580355A4 (fr) Transcription inverse à médiation par un oligonucléotide à tige-boucle modifié et pcr quantitative restreinte à espacement de bases
EP3693464A3 (fr) Compositions et procédés d'inhibition de l'expression des gènes de l'apolipoprotéine c-iii (apoc3)
WO2010080129A3 (fr) Agents allongés servant de substrats de dicer et procédés d'inhibition spécifique de l'expression d'un gène
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
WO2011123621A3 (fr) Monomères modifiés en 2' et 5' et oligonucléotides
WO2012142611A3 (fr) Séquençage de petites quantités d'acides nucléiques complexes
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
SG10201804076RA (en) Methods for multiplex detection of alleles associated with ophthalmic conditions
NZ601247A (en) Targeted genomic alteration
JP2012050447A5 (fr)
WO2012168307A3 (fr) Efficacité améliorée de recombinaison par inhibition d'une réparation de l'adn par nhej
WO2012078967A3 (fr) Compositions et procédés pour l'augmentation de la production d'érythropoïétine (epo)
WO2010006973A3 (fr) Compositions et procédés pour inhiber l’expression de gènes de récepteur tgf-bêta
WO2012178033A3 (fr) Arnsi de serpina1 : compositions et méthodes de traitement
WO2012115454A3 (fr) Procédé pour concentrer des cellules qui sont génétiquement modifiées par des nucléases
Cortez et al. microRNAs in cancer: from bench to bedside
WO2012177949A3 (fr) Compositions et procédés d'inhibition de l'expression de gènes de protéine c (proc)
WO2007147067A8 (fr) Procédés et compositions de régulation de l'évolution du cycle cellulaire
WO2009086428A3 (fr) Procédés et compositions destinés à augmenter l'expression génique
MX2019009305A (es) Oligonucleotido de cadena simple.
WO2013040393A3 (fr) Gènes contribuant à la survie de cellules cancéreuses
EP2570492A3 (fr) Méthode de detection de mutations de IL28B (RS8099917) et ITPA (RS1127354)